Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy (2024)
Sequence: WEARLARALARALARHLARALARALRACEA
| Experiment Id | EXP002461 |
|---|---|
| Paper | Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy |
| Peptide | RALA |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Set by N/P ratio (N/P=10 selected); exact mass/µM not reported |
| Rna Concentration | 2.5 µg mRNA per transfection (DC2.4 in Opti-MEM, serum-free) |
| Mixing Ratio | N/P = 10 (tested 1, 5, 10) |
| Formulation Format | mRNA/RALA polyplex (nanocomplex) |
| Formulation Components | RALA peptide + reporter mRNA (eGFP or mCherry) |
| Size Nm | |
| Zeta Mv | 26.20 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Mouse dendritic cell line DC2.4 |
| Animal Model | |
| Administration Route | |
| Output Type | Reporter expression / transfection efficiency; uptake imaging |
| Output Value | Higher GFP/mCherry signal at N/P=10 vs naked mRNA (qualitative; MFI highest at N/P=10) |
| Output Units | |
| Output Notes | Uptake shown by confocal; expression quantified by flow cytometry at 24 h; RALA binds mRNA by gel shift; ζ-potential +26.2 mV at N/P=10 |
| Toxicity Notes | CCK-8: N/P=10 least toxic vs naked mRNA, N/P=1, N/P=5 |
| Curation Notes |